Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE to appraise cryoablation and HIFU for prostate cancer

This article was originally published in Clinica

Executive Summary

The UK’s National Institute for Health and Clinical Excellence (NICE) is to appraise two “focal therapy” ablation technologies for the treatment of localised prostate cancer: cryoablation and high-intensity focused ultrasound (HIFU). The appraisals will take place under NICE’s interventional procedures programme, which assesses the efficacy and safety of rarely used or highly innovative techniques, with a view to increasing their use in the NHS. A provisional decision is expected to be issued for consultation in autumn 2011; the provisional publication date is end of 2011 or early-2012.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel